Japanese encephalitis virus strain SA 14-14-2 antigen (formaldehyde inactivated) clinical trials
Also written IC51 and IXIARO.
How each study uses japanese encephalitis virus strain SA 14-14-2 antigen (formaldehyde inactivated) is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the japanese encephalitis virus strain SA 14-14-2 antigen (formaldehyde inactivated) studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 30 Mar 2009 · Ixiaro · BLA 125280 (FDA, Purple Book)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2010 (6)
| Year | Studies |
|---|---|
| 2005 | 5 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 2 |
| 2010 | 6 |
| 2012 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 3
Valneva Austria GmbH (15) · Medical University of Vienna (1) · Helsinki University Central Hospital (1) · Singapore General Hospital (1)
Often tested with
Tested in the same studies.
Hepatitis A Vaccines (1) · Japanese Encephalitis Vaccines (1)
Studies
Open first, then newest update. How each study uses japanese encephalitis virus strain SA 14-14-2 antigen (formaldehyde inactivated) is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 18
- An Experimental Medicine Decipher of a Minimum Correlate of Cellular ImmunityRecruitingPhase 2Singapore General HospitalNCT05568953Written as IxiaroHow we know
- Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51CompletedPhase 3Valneva Austria GmbHNCT00594958Written as IC51How we know
- Immunogenicity Study of the Japanese Encephalitis Vaccine IC51CompletedPhase 3Valneva Austria GmbHNCT00604708Written as IC51How we know
- Safety and Tolerability of the Japanese Encephalitis Vaccine IC51CompletedPhase 3Valneva Austria GmbHNCT00605085Written as Japanese Encephalitis purified inactivated vaccine (IC51)How we know
- Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric PopulationCompletedPhase 3Valneva Austria GmbHNCT01041573Written as IC51 Japanese EncephalitisHow we know
- Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic CountriesCompletedPhase 3Valneva Austria GmbHNCT01047839Written as IC51How we know
- Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-StudyCompletedPhase 3Valneva Austria GmbHNCT01246479Written as IC51 has given in the parent study IC51-322How we know
- Cellular and Humoral Immunity in Elderly After Immunization With a Japanese Encephalitis VaccineCompletedPhase 4Medical University of ViennaNCT01398540Written as IXIAROHow we know
- Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post FillingCompletedPhase 3Valneva Austria GmbHNCT00776230Written as IC51How we know
- Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic CountryCompletedPhase 3Valneva Austria GmbHNCT01296360Written as IXIAROHow we know
- Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51CompletedPhase 3Valneva Austria GmbHNCT00595465Written as Japanese Encephalitis purified inactivated vaccineHow we know
- Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51CompletedPhase 3Valneva Austria GmbHNCT00595309Written as IC51How we know
- Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440CompletedPhase 3Valneva Austria GmbHNCT00596271Written as IC51How we know
- Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51CompletedPhase 3Valneva Austria GmbHNCT00595790Written as IC51How we know
- Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51CompletedPhase 3Valneva Austria GmbHNCT00595270Written as IC51How we know
- Immune Response in IXIARO Batch JEV09L37 Recipients Before and After RevaccinationWithdrawnPhase 1Valneva Austria GmbHNCT01559831Written as IXIAROHow we know
- This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly PopulationCompletedPhase 4Valneva Austria GmbHNCT01158599Written as IXIARO®How we know
- Ixiaro as Booster After Mouse-brain Derived Vaccines for Japanese EncephalitisCompletedPhase 3Helsinki University Central HospitalNCT01386827Written as C) primary immunizations with IxiaroHow we know
Given beside what is tested · 1 — japanese encephalitis virus strain SA 14-14-2 antigen (formaldehyde inactivated) is usual care or a partner of the new treatment
- A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.CompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02963909Written as IXIAROHow we know
As the comparator · 1 — what is tested is compared with japanese encephalitis virus strain SA 14-14-2 antigen (formaldehyde inactivated)
Codes
What other systems call japanese encephalitis virus strain SA 14-14-2 antigen (formaldehyde inactivated) · ClinicalTrials.gg INT016389
- UNII (FDA) DZ854I04ZEJAPANESE ENCEPHALITIS VIRUS STRAIN SA 14-14-2 ANTIGEN (FORMALDEHYDE INACTIVATED)Confirmed FDA, Wikidata
- Wikidata Q28859737japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)Confirmed FDA, Wikidata
- NCI Thesaurus C75796Japanese Encephalitis Virus Strain SA 14-14-2 Antigen (Formaldehyde Inactivated)Confirmed FDA, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | DZ854I04ZE | JAPANESE ENCEPHALITIS VIRUS STRAIN SA 14-14-2 ANTIGEN (FORMALDEHYDE INACTIVATED) | Confirmed FDA, Wikidata |
| Wikidata | Q28859737 | japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) | Confirmed FDA, Wikidata |
| NCI Thesaurus | C75796 | Japanese Encephalitis Virus Strain SA 14-14-2 Antigen (Formaldehyde Inactivated) | Confirmed FDA, Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.